Executive Team


President, Chief Executive Officer and Member of the Board

Dr. Coles joined Onyx in March 2008 as President, Chief Executive Officer, and a member of its board of directors. Prior to joining Onyx, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb Company, including Senior Vice President of Strategy and Policy; Senior Vice President of Marketing and Medical Affairs, Neuroscience/Infectious Diseases/Dermatology; Vice President, Western Area Sales Cardiovascular and Metabolic Business Unit for U.S. Primary Care; and Vice President, Cardiovascular Global Marketing. From 1992 until 1996, Dr. Coles also held a number of positions of increasing responsibility at Merck & Co., Inc, including Vice President of the Hypertension and Heart Failure Business Group. 

Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master's degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a trustee and member of the Executive Committee for the Johns Hopkins University Board of Trustees and a trustee of Boston Medical Center. He is also a member of the board of the Biotechnology Industry Organization (BIO) and FoldRx, Inc., a privately held biotech company in Cambridge, MA.


Executive Vice President and Chief Operating Officer

Laura A. Brege joined Onyx in June 2006 as executive vice president and chief business officer. In that role, she oversaw the expansion of key corporate capabilities and strengthened Onyx's financial position by significantly adding to its cash reserves. She was promoted to her current position in October 2007, where she is responsible for the sales and marketing, medical affairs, legal, and compliance functions. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm. Prior to Red Rock, she was the senior vice president and chief financial officer at COR Therapeutics. Earlier in her career, Ms. Brege served as vice president and chief financial officer at Flextronics and vice president and treasurer of The Cooper Companies. Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago. She serves on the boards of Angiotech Pharmaceuticals, Inc. and The Ohio University Foundation.


Executive Vice President and Chief Financial Officer

Matthew K. Fust joined Onyx in January 2009 as executive vice president and chief financial officer. Prior to joining Onyx, Mr. Fust was executive vice president and chief financial officer at Jazz Pharmaceuticals, which he joined in 2003. From 2002 until 2003, he was chief financial officer at Perlegen Sciences, a biotechnology company. Previously, he was senior vice president and chief financial officer at ALZA Corporation where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Anderson Consulting. Mr. Fust earned an undergraduate degree in accounting from the University of Minnesota and an MBA from Stanford University. He serves as a member of the board of directors for Sunesis Pharmaceuticals.



Ted W. Love, M.D. joined Onyx in January 2010 as Executive Vice President and Head of Research and Development. Prior to joining Onyx, Dr. Love was President, Chief Executive Officer and Chairman of the Board of Directors at Nuvelo, which he joined in 2001. Previously, he served as Senior Vice President of Development at Theravance, Inc. Earlier in his career, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as Chairman of Genentech’s Product Development Committee. Dr. Love earned his undergraduate degree in molecular biology from Haverford College and his medical degree at Yale Medical School. Dr. Love completed his residency and fellowship training in internal medicine and cardiology at Harvard Medical School and Massachusetts General Hospital, where he later served on the faculty. He currently serves on the Board of Directors of Affymax, Inc., Santarus, Inc., ARCA biopharma, Inc., and on the California Institute for Regenerative Medicine (CIRM) Independent Citizens’ Oversight Committee.


Chief Medical Officer

Michael G. Kauffman, M.D., Ph.D., joined Onyx in November 2009 as the interim chief medical officer. Most recently, Dr. Kauffman was chief medical officer at Proteolix, Inc., after having served on their board of directors. At Proteolix, he was responsible for the clinical advancement of carfilzomib as well as PR-047. Prior to joining Proteolix, Dr. Kauffman was president and chief executive officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008. From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc. (now a subsidiary of Takeda Pharmaceutical Company), where he played a key role in the development of the proteasome inhibitor VELCADE®. Earlier in his career, he served as medical director at Biogen Corporation (now Biogen Idec). Dr. Kauffman earned his undergraduate degree in biochemistry from Amherst College and his M.D. and Ph.D in molecular biology and biochemistry from Johns Hopkins. He trained in Internal Medicine and Rheumatology at Beth Israel Deaconess Hospital and the Massachusetts General Hospital.


Senior Vice President, Corporate Development

Juergen Lasowski, Ph.D., joined Onyx in May 2008 as senior vice president of corporate development. Before joining Onyx, he was the senior vice president of corporate development at NPS Pharmaceuticals. Previously, Dr. Lasowski held several positions at Sanofi-Aventis and its predecessor companies in business development and strategy positions. Throughout his career, Dr. Lasowski has completed over 25 different business transactions across three continents including North America, Europe and Asia. Dr. Lasowski earned his MBA from INSEAD, France, and his Ph.D. in organic chemistry from the University of Mainz, Germany.


sENIOR Vice President, gENERAL cOUNSEL

Suzanne M. Shema, J.D. joined Onyx in August 2009 as senior vice president, general counsel.  Prior to joining Onyx, Ms. Shema was senior vice president and general counsel of law and compliance at ZymoGenetics, which she joined in 2001.  Before ZymoGenetics, Ms. Shema served as general counsel at aQuantive, Inc.   She also served as associate general counsel at Research Corporation Technologies, Inc.  Prior to Research Corporation Technologies, Ms. Shema served as associate general counsel at NeoRx Corporation.  Earlier in her career, she served as an associate at the law firm of Seed and Berry.  Ms. Shema earned an undergraduate degree in chemistry from the University of Texas, a master’s degree in chemistry from the University of Washington and a J.D. from the University of Washington.


Vice President of Organizational Learning, Development, and Human Resources

Judy Batlin has served as Onyx's vice president of organizational learning, development, and human resources since February 2008, and had previously served as an organization development consultant at Onyx since 2005. Ms. Batlin specializes in developing leadership competencies and overall effectiveness of teams and individual employees. She has over twenty years of experience in the biotechnology and pharmaceutical industry, and during her career has collaborated with a variety of organizations such as Acologix, Exelixis, Iconix Pharmaceuticals, Genentech, Pharmacopeia, Celera, Stanford Medical Center and Clinics, Chiron, and Berlex. Earlier in her career, Ms. Batlin served as director of organizational learning, as well as director of staffing and employee relations for Chiron Corporation. Previously, she held the position of associate director of human resource development at Berlex Laboratories.


Vice President, Corporate Communications and Investor Relations

Julie Wood joined Onyx in May 2003 to manage internal and external communications. She has an extensive background in investor relations and corporate communications, with a particular emphasis on the life sciences. Prior to Onyx, Ms. Wood was senior director of investor relations and corporate communications at Caliper Technologies Corp. Ms. Wood has served in a similar capacity at Sangamo BioSciences and Chiron Corporation. She earned her undergraduate degree from Stanford University and has an MBA from Duke University.